ACLY and autoimmune polyendocrinopathy: However, in recent years, two interventional clinical trials have been carried out whereby patients with triple positivity for APS (i.e., concomitant aCL, aβ2-GPI and LA) have been randomized to receive either vitamin K antagonists or rivaroxaban (an anti-factor Xa direct inhibitor).